Share |
30 September 2020

Highlights

Eye-drops to treat diabetic retinopathy: update on EUROCONDOR clinical trial

amb eyedropA group of leading European eye specialists, scientists and basic researchers will gather in Padova on 17 May 2014 to discuss the progress of the EUROCONDOR clinical trial which is testing the safety and efficiency of an innovative eye-drop treatment to prevent the development of diabetic retinopathy in people living with diabetes.

Diabetic retinopathy is an eye disease that occurs in people living with diabetes. It involves changes in the tiny blood vessels that nourish the retina at the back of the eye which can ultimately lead to severe loss of vision or even blindness. Today, diabetic retinopathy is the leading cause of preventable blindness among working-age individuals in developed countries.

Current treatments of diabetic retinopathy tend to be costly, invasive and have significant side-effects. They also tend to be applicable at more advanced stage of the disease.

In a move to alleviate the considerable social, economic and human burden caused by diabetic retinopathy, a consortium of leading scientists, eye specialists and basic researchers joined forces under the EUROCONDOR project to test an innovative eye-drop treatment to see whether it can prevent diabetic retinopathy or stop its development at an early stage.

Scientific consortium to give update following-up EASD Eye Complications Study Group Meeting this May

Members of the EUROCONDOR consortium will give an update on the research project right after the Eye Complications Study Group of the European Association for the Study of Diabetes (EASDec) annual meeting in Padova on 17 May.

The EUROCONDOR clinical trial started in February 2013 in 11 clinical centres across the EU. Partners will provide an update on the progress of the trial, as premilinary results are already shared with the wider scientific community.Project partner AIBILI, the Association for Innovation and Biomedical Research on Light (Coimbra, Portugal), is attending the 2014 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Orlando (Florida), where it will be presenting the project's baseline data.

You can find more information about the EUROCONDOR research on the project's profileurocondor logoe on HorizonHealth.eu or on the project's website.

The EUROCONDOR research project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278040.